AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

VRDN · NASDAQ · Biotechnology

Viridian Therapeutics (VRDN)

Enters commercial stage with Lumvoa, an intravenous IGF-1R antibody for thyroid eye disease.

$21.37

vs last close−0.75 (−3.40%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	0	0	0	0	0	0	0	0	71	0	0	0
Cost of revenue	0	0	0	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	0	71	0	0	0
	51	72	56	72	84	88	94	107	111	123	116	127
Research & development	30	39	41	56	69	72	77	87	86	89	78	72
	21	33	15	16	14	16	17	20	24	34	39	55
General & administrative	21	33	15	16	14	16	17	20	24	34	39	55
Other expenses	0	0	0	0	0	0	0	0	0	0	0	0
Operating income	−51	−71	−56	−72	−83	−87	−94	−107	−40	−123	−116	−126
	4	5	7	7	7	8	7	6	5	2	11	−1
Interest income	4	6	8	8	8	9	8	7	6	8	8	8
Interest expense	1	1	1	1	1	1	1	1	1	7	3	8
Other non-operating income	0	−6	−8	−8	−8	−9	−8	−7	−6	−9	−15	−7
Income before tax	−48	−67	−49	−65	−77	−80	−87	−101	−35	−120	−105	−127
Net income from continuing operations	−48	−67	−49	−65	−77	−80	−87	−101	−35	−120	−105	−127
Net income	−48	−67	−49	−65	−77	−80	−87	−101	−35	−120	−105	−127
EPS, basic	−$1.09	−$1.35	−$0.79	−$1.02	−$1.15	−$0.81	−$0.87	−$1.23	−$0.34	−$1.11	−$1.03	−$1.05
EPS, diluted	−$1.09	−$1.35	−$0.79	−$1.02	−$1.15	−$0.81	−$0.87	−$1.23	−$0.34	−$1.11	−$1.03	−$1.05
Weighted average shares, basic	44	50	61	64	66	80	81	82	82	85	102	108
Weighted average shares, diluted	44	50	61	64	66	80	81	82	82	85	102	108
EBITDA	−51	−66	−48	−64	−76	−79	−86	−100	−34	−114	−101	−119
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	−51	−66	−48	−64	−76	−79	−86	−100	−34	−114	−101	−119